Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Total Non-Current Liabilities (2024 - 2025)

Maze Therapeutics has reported Total Non-Current Liabilities over the past 2 years, most recently at $41.1 million for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 3.75% to $41.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41.1 million through Dec 2025, down 3.75% year-over-year, with the annual reading at $41.1 million for FY2025, 3.75% down from the prior year.
  • Total Non-Current Liabilities was $41.1 million for Q4 2025 at Maze Therapeutics, down from $41.5 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $42.7 million in Q4 2024 and troughed at $39.8 million in Q1 2025.